Lilly Enlists Boehringer for Duloxetine
Executive Summary
A $280 million deal with Eli Lilly for duloxetine allows Boehringer Ingelheim to expand its presence in both urology and CNS--thanks to Lilly's deluge of near-market therapeutics, which has required the firm for the first time to enter a significant co-promotion deal for one of its own important products.
You may also be interested in...
Sleeping Giant: Europe's Slice of the Global UI Market
The near-dormant global market for urinary incontinence treatments is poised to erupt in the second half of this decade-Novartis' recent acquisition of Pfizer's darifenacin introduces one more global player to the mix. But for existing and novel drug therapies to succeed in the fragmented and particularly underdeveloped European market companies must first recognize the challenges presented by cultural taboo and country-specific regulation.
Boehringer's Spiriva: Advancing COPD Therapy
Boehringer Ingelheim's new COPD treatment, Spiriva, could be a blockbuster--particularly if its worldwide marketing partner Pfizer can increase diagnosis of the disease and expand COPD drugs' prescribing base from specialists to GPs. But, complicating matters for Boehringer, Pfizer--through its proposed acquisition of Pharmacia--will also market the PDE-4 inhibitor roflumilast, Altana's next-generation COPD therapy.
Lilly & Boehringer: When You Gotta Partner, You Gotta Partner
Lilly's co-promotion with Boehringer Ingelheim of duloxetine is the first time the American company has signed a major marketing deal for one of its own products. The company notes the collaboration is part of its broad commitment to partnering and that the market is intensely competitive. But the choice of duloxetine--the launch of which may be delayed indefinitely because of manufacturing problems--also represents Lilly's lowest-risk option for subsidizing the launches, and maximizing the returns from, potentially eight new products over the next few years.